Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02375022|
Recruitment Status : Unknown
Verified March 2015 by Qiong Zhao, Zhejiang University.
Recruitment status was: Recruiting
First Posted : March 2, 2015
Last Update Posted : March 24, 2015
Jiangsu Simcere Pharmaceutical Co., Ltd.
Beta Pharma, Inc.
Information provided by (Responsible Party):
Qiong Zhao, Zhejiang University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||March 2016|
|Estimated Study Completion Date :||March 2016|